FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition for treating Parkinson's disease, comprising a therapeutically effective amount of a first compound corresponding in structure to formula (I), or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a second compound of structure (II) or pharmaceutically acceptable salt thereof. In formula (I), each of R1 and R2 is independently selected from a group consisting of hydrogen, -P(O)(OH)2 and -R5-O-P(O)(OH)2; R5 is C1-C4-alkyl; R6 denotes hydrogen or C1-C4-alkyl; and wherein at least one of R1 and R2 is -P(O)(OH)2 or -R5-O-P(O)(OH)2. In formula (II), each of R3 and R4 is independently selected from a group consisting of hydrogen, -P(O)(OH)2 and -R5-O-P(O)(OH)2; R5 is C1-C4-alkyl; R6 denotes hydrogen or C1-C4-alkyl; and wherein at least one of R3 and R4 is -P(O)(OH)2 or -R5-O-P(O)(OH)2. Invention also relates to a pharmaceutical composition containing specific compounds of formulas (I) and (II), a method of treating Parkinson's disease and a compound, corresponding by structure to formula (I).
EFFECT: carbidopa and L-DOPA prodrugs are proposed and used for treating Parkinson's disease.
14 cl, 22 dwg, 18 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
| NUCLEOSIDES WITH ACTIVITY AGAINST HEPATITIS B VIRUS | 1999 |
|
RU2237479C2 |
| β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV | 2016 |
|
RU2764767C2 |
| PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF LEVODOPA PRODRUG AND METHODS OF USING | 2010 |
|
RU2537137C2 |
| MODIFIED 2- AND 3-NUCLEOSIDES AND USE THEREOF TO PRODUCE MEDICINAL AGENT, HAVING HEPATITIS C INHIBITING ACTIVITY | 2003 |
|
RU2437892C2 |
| PROMEDICINES OF MODIFIED 2'- AND 3'-NUCLEOSIDES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | 2003 |
|
RU2366661C2 |
| MODIFIED 2'- AND 3'-NUCLEOSIDES AND USE THEREOF FOR PREPARING DRUG FOR TREATING FLAVIVIRIDAE INFECTIONS | 2011 |
|
RU2483075C2 |
| MODIFIED CYTOTOXINS AND THERAPEUTIC APPLICATION THEREOF | 2016 |
|
RU2721949C2 |
| BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | 2018 |
|
RU2776846C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2015 |
|
RU2733405C2 |
